Literature DB >> 17085111

The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program.

Mike M Nguyen1, Inderbir S Gill, Lars M Ellison.   

Abstract

PURPOSE: The incidence of renal cancer is increasing, while cases series suggest that tumor size is decreasing. This has important implications for treatment planning. We evaluated national trends in renal cancer size and observed survival in patients diagnosed in the 3 periods 1988 to 1992, 1993 to 1997 and 1998 to 2002.
MATERIALS AND METHODS: From the Surveillance, Epidemiology, and End Results database we identified 29,053 patients diagnosed with primary renal cancer. Patients were stratified into size categories and 5-year time cohorts. Size distribution was compared across cohorts. Kaplan-Meier survival curves and Cox proportional hazards modeling were used to examine trends in overall and stage specific survival.
RESULTS: From 1988 through 2002 renal tumor size decreased from 66.8 to 58.6 mm, while the age adjusted incidence of renal cancer increased from 8.6 to 11.2 cases per 100,000 individuals. Kaplan-Meier analysis showed steadily deteriorating survival with increased cancer size above 4 cm with a median survival of 105 months for 4 to 7 cm vs 46 months for more than 7 cm. Cox modeling demonstrated significantly improved survival in patients diagnosed in the latter cohorts. With adjustment for size the latter cohorts remained significantly improved compared to the earliest cohort, although the 1998 to 2002 cohort was no longer significantly different than the 1993 to 1997 cohort.
CONCLUSIONS: Nationally renal tumor size at presentation has steadily and consistently decreased. Patients more recently diagnosed had improved survival, which could be attributable to decreased tumor size in the latter cohorts. Patients more recently diagnosed also demonstrated a relative survival advantage independent of size compared to the earliest patients studied.

Entities:  

Mesh:

Year:  2006        PMID: 17085111     DOI: 10.1016/j.juro.2006.07.144

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  88 in total

1.  Canadian guidelines for the management of small renal masses (SRM).

Authors:  Michael A S Jewett; Ricardo Rendon; Louis Lacombe; Pierre I Karakiewicz; Simon Tanguay; Wassim Kassouf; Mike Leveridge; Ilias Cagiannos; Anil Kapoor; Stephen Pautler; Darrel Drachtenberg; Ronald Moore; Martin Gleave; Andrew Evans; Massoom Haider; Antonio Finelli
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

2.  A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.

Authors:  Hui Huang; Michael Menefee; Maureen Edgerly; Sen Zhuang; Herb Kotz; Marianne Poruchynsky; Lyn Mickley Huff; Susan Bates; Tito Fojo
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Evaluation of the variant anatomical disposition of the renal hilar structures in South Indian adult human cadavers and its cinical implications.

Authors:  Naveen Kumar; Anitha Guru; Ashwini Aithal P; Surekha D Shetty; Satheesha Nayak B; Narendra Pamidi
Journal:  J Clin Diagn Res       Date:  2013-08-01

4.  Assessment of multiphasic contrast-enhanced MR textures in differentiating small renal mass subtypes.

Authors:  Uyen N Hoang; S Mojdeh Mirmomen; Osorio Meirelles; Jianhua Yao; Maria Merino; Adam Metwalli; W Marston Linehan; Ashkan A Malayeri
Journal:  Abdom Radiol (NY)       Date:  2018-12

5.  Preoperative nomogram predicting 12-year probability of metastatic renal cancer.

Authors:  Ganesh V Raj; R Houston Thompson; Bradley C Leibovich; Michael L Blute; Paul Russo; Michael W Kattan
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

Review 6.  Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.

Authors:  Wilfred D Stein; Hui Huang; Michael Menefee; Maureen Edgerly; Herb Kotz; Andrew Dwyer; James Yang; Susan E Bates
Journal:  Cancer J       Date:  2009 Sep-Oct       Impact factor: 3.360

7.  Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis.

Authors:  Mark W Ball; Michael A Gorin; Sam B Bhayani; Craig G Rogers; Michael D Stifelman; Jihad H Kaouk; Homayoun Zargar; Susan Marshall; Jeffrey A Larson; Haider M Rahbar; Bruce J Trock; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Urol Oncol       Date:  2014-12-11       Impact factor: 3.498

8.  Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings.

Authors:  Joel Prince; Eric Bultman; Louis Hinshaw; Anna Drewry; Michael Blute; Sara Best; Fred T Lee; Timothy Ziemlewicz; Meghan Lubner; Fangfang Shi; Stephen Y Nakada; E Jason Abel
Journal:  J Urol       Date:  2014-12-11       Impact factor: 7.450

9.  Rising incidence of renal cell carcinoma in Ireland.

Authors:  Opeyemi A Falebita; Silvia Mancini; Eamonn Kiely; Harry Comber
Journal:  Int Urol Nephrol       Date:  2008-06-20       Impact factor: 2.370

10.  Upper gastrointestinal bleeding revealing the stomach metastases of renal cell carcinoma.

Authors:  Rizwan Kibria; Kanan Sharma; Syed A Ali; Pallavi Rao
Journal:  J Gastrointest Cancer       Date:  2009-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.